ARS Pharmaceuticals, Inc. (SPRY) Stock

ARS Pharmaceuticals, Inc. (SPRY) is a Healthcare stock trading at $9.64 (as of 2026-06-18), with a market capitalization of $900.68M and a trailing P/E of -4.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ARS Pharmaceuticals, Inc. develops ARS-1, an intranasal epinephrine spray intended for people at risk of severe allergic reactions to foods, medications, and insect bites, along with their families. The company’s product portfolio includes Neffy, a low-dose intranasal epinephrine nasal spray.

Valuation — source: SEC EDGAR (first-party)
Price$9.64
Market Cap$900.68M
P/E Ratio-4.5
EV / EBITDA-4.8
Price / Book14.69
Price / Sales9.10
DCF Value (model)$-29.91
DCF Upside vs Price-410.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$84.28M
Net Margin-203.3%
Return on Equity-322.9%
Debt / Equity1.57
Current Ratio4.94
Revenue Growth (YoY)184.5%
EPS Growth (YoY)74.3%
FCF Growth (YoY)10.1%
Financial Health — source: SEC EDGAR
Altman Z-Score0.78 (distress)
Valuation vs Sector & Industry
Stock P/E-4.5
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-121.6%
vs Industry-126.3%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($87.21M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORichard E. Lowenthal
Employees155
CountryUS
IPO Date2020-12-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Savara Inc. (SVRA)
  • Omeros Corporation (OMER)
  • Amphastar Pharmaceuticals, Inc. (AMPH)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • Inhibrx Biosciences, Inc. (INBX)
  • Iovance Biotherapeutics, Inc. (IOVA)
  • Novavax, Inc. (NVAX)
  • Sana Biotechnology, Inc. (SANA)
SPRY earnings history · SPRY institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.